MedPath

Medical University of Vienna

Medical University of Vienna logo
🇦🇹Austria
Ownership
Private
Established
1365-01-01
Employees
1K
Market Cap
-
Website
http://www.meduniwien.ac.at

Clinical Trials

1.2k

Active:106
Completed:582

Trial Phases

6 Phases

Early Phase 1:4
Phase 1:117
Phase 2:104
+3 more phases

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (844 trials with phase data)• Click on a phase to view related trials

Not Applicable
405 (48.0%)
Phase 4
160 (19.0%)
Phase 1
117 (13.9%)
Phase 2
104 (12.3%)
Phase 3
51 (6.0%)
Early Phase 1
4 (0.5%)
phase_1_2
2 (0.2%)
1 (0.1%)

ImmunoMRI for Assessment of Tumor-associated Macrophages

Not Applicable
Not yet recruiting
Conditions
DLBCL - Diffuse Large B Cell Lymphoma
Interventions
Drug: MRI contrast-enhancing agents
First Posted Date
2025-07-15
Last Posted Date
2025-07-15
Lead Sponsor
Medical University of Vienna
Target Recruit Count
60
Registration Number
NCT07066436
Locations
🇦🇹

Medical University of Vienna, Vienna, Austria

Long-term Effect of Dupilumab in N-ERD

Not yet recruiting
Conditions
Asthma Bronchiale
Nasal Polyposis
Chronic Rhinosinusitis (CRS)
NSAID-Induced Asthma
NSAIDs Hypersensitivity
First Posted Date
2025-07-03
Last Posted Date
2025-07-08
Lead Sponsor
Medical University of Vienna
Target Recruit Count
30
Registration Number
NCT07049978
Locations
🇦🇹

Medical University of Vienna, Vienna, Austria

Effect of Tezepelumab on Barrier Function in Severe Asthmatic Patients With and Without Comorbid Chronic Rhinosinusitis With Nasal Polyps

Not Applicable
Not yet recruiting
Conditions
Asthma Bronchiale
Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Interventions
First Posted Date
2025-07-01
Last Posted Date
2025-07-01
Lead Sponsor
Medical University of Vienna
Target Recruit Count
20
Registration Number
NCT07046117
Locations
🇦🇹

Medical University of Vienna, Vienna, Austria

DETACT sEvere asThmAtiC paTients - a Pilot Study

Recruiting
Conditions
Asthma
Interventions
First Posted Date
2025-06-17
Last Posted Date
2025-06-17
Lead Sponsor
Medical University of Vienna
Target Recruit Count
10
Registration Number
NCT07025200
Locations
🇦🇹

Medical University of Vienna, Clinic of Internal Medicine II, Department of Pulmonology, Vienna, Austria

MultiCPR: The Influence of Ventilations on Mental Arithmetics

Not Applicable
Recruiting
Conditions
Multitasking Behavior
First Posted Date
2025-05-22
Last Posted Date
2025-07-08
Lead Sponsor
Medical University of Vienna
Target Recruit Count
38
Registration Number
NCT06986226
Locations
🇦🇹

Academic Simulation Center, Vienna, Austria

  • Prev
  • 1
  • 2
  • 3
  • 4
  • 5
  • 211
  • Next

News

Diabetes Drug Pioglitazone Shows Promising Anti-Tumor Effects in Prostate Cancer

Researchers from the Medical University of Vienna have discovered that PPAR𝛾, a protein targeted by type 2 diabetes medications, can influence prostate cancer cell growth.

Respiratory Function Monitoring Improves Supraglottic Airway Device Placement in Neonates, Study Shows

A novel pilot study demonstrates that respiratory function monitoring (RFM) significantly reduces the number of attempts needed for successful supraglottic airway device placement in neonates, including those under 1500g.

Low-Dose Rituximab Shows Transient Efficacy in Autoimmune Hemolytic Anemia

A phase II pilot trial investigated very low doses of rituximab in patients with autoimmune hemolytic anemia (AIHA) to suppress CD20+ cell counts.

MACE Endpoint Faces Scrutiny in Cardiovascular Trials

The major adverse cardiac events (MACE) endpoint, a long-standing standard in cardiovascular trials, is being questioned for its clinical relevance.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.